The fen-phen summer: Weight loss brings unexpected results

Plutowski, Shelly
April 1998
Communication World;Apr/May98, Vol. 15 Issue 5, p28
Trade Publication
Reports on the successful effort of the Mayo Clinic's division of communication in Rochester, Minnesota to ban a weight loss drug because users are developing valvular heart disease. Presentation of facts; Challenge of communicating study results without a formal scientific publication; Use of the Internet and assistance of the US Food and Drug Administration.


Related Articles

  • GPs should join debate on potential risk versus reward of obesity drug. Castaneda, Reynald // New Zealand Doctor;10/8/2014, p14 

    The article focuses on the debate by general practitioners (GP) and clinicians in New Zealand on the risks and reward of the obesity drug phentermine.

  • The Straight Dope On Weight-Loss Drugs. Fentress, Debbie; Agnew, Bruce // Diabetes Forecast;Apr2002, Vol. 55 Issue 4, p51 

    Provides information on weight-loss drugs, Xenical, Meridia and phentermine. Overview of studies on the drugs; Side effects of weight loss drugs; Contents of the drugs. INSET: Beware herbal remedies.

  • The fen-phen furor: Advice for users. E.B. // Medical Update;Feb98, Vol. 21 Issue 8, p3 

    Focuses on the adverse effects of the drug combination fenfluramine and dexfenfluramine, drugs used to promote weight loss. Abnormalities possibly caused by the drugs; Reason for manufacturers withdrawal of the drugs from the market; Suggestion for patients who took the drug combination to see...

  • FDA Warning on Chinese Diet Pills Containing Fenfluramine.  // FDA Consumer;Sep/Oct2002, Vol. 36 Issue 5, p7 

    Reports on warnings about Chinese weight-loss products from the U.S. Food and Drug Administration. Risks from Chaso Diet Capsules and Chaso Genpi; Deaths in Japan; Danger of the toxic ingredient, aristolochic acid; Lethal combination of fenfluramine and phentermine.

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • Fen-phen: Risky for dieters in any form.  // Consumer Reports;Sep97, Vol. 62 Issue 9, p6 

    Reports on the dangers of the diet drug fen-phen and its herbal counterpart, Herbal Fen-Phen. Where Herbal Fen-Phen is sold; Why the US Food and Drug Administration recommended against the use of fen-phen; Deaths related to the use of fen-phen.

  • Every New Mexico drugstore sued over phen-fen. Conlan, Michael F. // Drug Topics;12/7/98, Vol. 142 Issue 23, p24 

    Reports on the state lawsuit against 281 community pharmacies in New Mexico filed at the District Court in Santa Fe in 1998. Allegations of the plaintiffs regarding the manufacturers and sellers of fenfluramine-phentermine; Highlights of the case.

  • Phen-fen frenzy. Clive, Teagan // Joe Weider's Muscle & Fitness;Jan97, Vol. 58 Issue 1, p100 

    Focuses on the phentermine-fenfluramine (phen-fen) drug combination for weight loss. Effectiveness of the combination; Side effects; Disagreement between physicians on the drug combination; Background information on the phen-fen saga; Drug's potential for abuse. INSETS: Who gets phen-fen--and...

  • Specific Medications for Weight Loss. Jin, Jill // JAMA: Journal of the American Medical Association;8/18/2015, Vol. 314 Issue 7, p742 

    The article assesses medications for weight loss. Medications addressed include orlistat, lorcaserin, and the combination of phentermine and topiramate. Also addressed are the combination of bupropion and naltrexone and the medication liraglutide. Other topics include the risks of stimulant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics